Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibrilatazar - Ability Pharmaceuticals

Next Previous
Drug Profile

Ibrilatazar - Ability Pharmaceuticals

Alternative Names: ABTL-0812; LAM-182; LP-10218; SCLN-0812

Latest Information Update: 12 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lipopharma
  • Developer Ability Pharmaceuticals; SciClone Pharmaceuticals; Vall d-Hebron Research Institute
  • Class Antineoplastics; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Autophagy stimulants; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Biliary cancer; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Pancreatic cancer

Highest Development Phases

  • Phase II Endometrial cancer; Pancreatic cancer; Squamous cell cancer
  • Phase I/II Neuroblastoma; Solid tumours
  • No development reported Biliary cancer; Non-small cell lung cancer

Most Recent Events

  • 04 Jun 2025 Phase-I/II clinical trials in Neuroblastoma (In children, In adolescents, In infants, Second-line therapy or greater) in Spain (PO) (EudraCT2023-504246-64-02)
  • 04 Jun 2025 Phase-I/II clinical trials in Solid tumours (In adolescents, In children, In infants, Second-line therapy or greater) in Spain (PO) (EudraCT2023-504246-64-02)
  • 09 Sep 2024 Efficacy, pharmacokinetics and adverse events data from a phase II trial in Endometrial cancer released by ability pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top